ReviewMedical principles and practice : international journal of the Kuwait University, Health Science Centre2013
Tumor markers in clinical practice: a review focusing on common solid cancers.
Review in Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 4 syntheses or guidelines pooled it, 268 citations in OpenAlex.
- The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review.BMC cancer · 2017Pooled it
- KLHL21, a novel gene that contributes to the progression of hepatocellular carcinoma.BMC cancer · 2016Pooled it
- Blood CEA levels for detecting recurrent colorectal cancer.The Cochrane database of systematic reviews · 2015Pooled it
- Serum carbohydrate antigen 19-9 and prognosis of patients with gastric cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- The specificity trap in routine tumor biomarker interpretation: Advancing the 3PM-based clinical decision framework to benefits of patients.The EPMA journal · 2026Review
- Current opinions on CEA in the diagnosis and prognosis of colorectal cancer.Translational oncology · 2026Review
- Exploring the Clinical Landscape of Long Non-coding RNAs in Cancer Diagnosis and Therapy.Biochemical genetics · 2026Review
- Regulated cell death plasticity in cancer: thresholds, reversibility, and therapeutic failure.Journal of translational medicine · 2026Review
- CT radiomics for survival risk stratification in resectable colorectal liver metastases: a multi-centre study.Scientific reports · 2026Article
- Article
- Diagnostic utility of postmortem serum tumor markers for identifying primary malignancies: A forensic evaluation of six markers.Forensic science, medicine, and pathology · 2026Article
- Article
- The impact of anxiety and affective disorders on breast cancer screening in women in Puerto Rico.PloS one · 2026Article
- Purple Urine Bag Syndrome in a 26-Year-Old Woman Living with HIV and Metastatic Spinal Cord Compression: A Case Report.International medical case reports journal · 2026Article
- Diagnostic Value of CA-125 and Other Tumor Biomarkers in Children with Suspected Malignancy: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- An effective and affordable blood test for lung cancer early detection using four protein markers and artificial intelligence.Translational lung cancer research · 2025Article
- New breast cancer marker BF-09 is overexpressed in tumor extracts and secreted in serum.Biochemistry and biophysics reports · 2025Article
- Article
- Identification of new tissue markers for the monitoring and standardization of penile cancer according to the degree of differentiation.Histology and histopathology · 2025Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor markers are playing an increasingly important role in cancer detection and management. These laboratory-based tests are potentially useful in screening for early malignancy, aiding cancer diagnosis, determining prognosis, surveillance following curative surgery for cancer, up front predicting drug response or resistance, and monitoring therapy in advanced disease. Clinically useful markers include fecal occult blood testing in screening for early colorectal cancer, carcinoembryonic antigen in the management of patients with colorectal cancer, both α-fetoprotein and human chorionic gonadotrophin in the management of patients with non-seminomatous germ cell tumors, CA 125 for monitoring therapy in patients with ovarian cancer, estrogen receptors for predicting response to hormone therapy in breast cancer, human epidermal growth factor receptor 2 for the identification of women with breast cancer likely to respond to trastuzumab (Herceptin) and KRAS mutational status for identifying patients with advanced colorectal cancer likely to benefit from treatment with the anti-epidermal growth factor receptor antibodies, cetuximab and panitumumab. Although widely used, the value of prostate-specific antigen screening in reducing mortality from prostate cancer is unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.